PIMT is a novel and potent suppressor of endothelial activation
eLife · 2023
DOI: 10.7554/elife.85754 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Chen Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, Thomas Jefferson University, Philadelphia, United States. Hauptthemen laut MEDLINE: Lipopolysaccharides, TNF Receptor-Associated Factor 6, Protein D-Aspartate-L-Isoaspartate Methyltransferase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, American Heart Association, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Proinflammatory agonists provoke the expression of cell surface adhesion molecules on endothelium in order to facilitate leukocyte infiltration into tissues. Rigorous control over this process is important to prevent unwanted inflammation and organ damage. Protein L-isoaspartyl O-methyltransferase (PIMT) converts isoaspartyl residues to conventional methylated forms in cells undergoing stress-induced protein damage. The purpose of this study was to determine the role of PIMT in vascular homeostasis. PIMT is abundantly expressed in mouse lung endothelium and PIMT deficiency in mice exacerbated pulmonary inflammation and vascular leakage to LPS(lipopolysaccharide). Furthermore, we found that PIMT inhibited LPS-induced toll-like receptor signaling through its interaction with TNF receptor-associated factor 6 (TRAF6) and its ability to methylate asparagine residues in the coiled-coil domain. This interaction was found to inhibit TRAF6 oligomerization and autoubiquitination, which prevented NF-κB transactivation and subsequent expression of endothelial adhesion molecules. Separately, PIMT also suppressed ICAM-1 expression by inhibiting its N-glycosylation, causing effects on protein stability that ultimately translated into reduced EC(endothelial cell)-leukocyte interactions. Our study has identified PIMT as a novel and potent suppressor of endothelial activation. Taken together, these findings suggest that therapeutic targeting of PIMT may be effective in limiting organ injury in inflammatory vascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Translational Medicine, Thomas Jefferson University, Philadelphia, United States.
- Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
- Quantitative Proteomics Resource Center, University of Pennsylvania, Philadelphia, United States.
- Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, United States.
ORCID-Profile: Chen Zhang, Kyosuke Kazama, Lu Wang, Jianxin Sun
Förderung
- NHLBI NIH HHS
- American Heart Association
- National Heart, Lung, and Blood Institute
Zitieren
APA
Zhang, C., Guo, Z. F., Liu, W., Kazama, K., Hu, L., Sun, X., Wang, L., Lee, H., Lu, L., Yang, X. F., Summer, R., & Sun, J. (2023). PIMT is a novel and potent suppressor of endothelial activation. eLife. https://doi.org/10.7554/elife.85754
Vancouver
Zhang C, Guo ZF, Liu W, Kazama K, Hu L, Sun X, et al. PIMT is a novel and potent suppressor of endothelial activation. eLife. 2023. doi:10.7554/elife.85754
BibTeX
@article{Zhang2023,
author = {Zhang, Chen and Guo, Zhi-Fu and Liu, Wennan and Kazama, Kyosuke and Hu, Louis and Sun, Xiaobo and Wang, Lu and Lee, Hyoungjoo and Lu, Lin and Yang, Xiao-Feng and Summer, Ross and Sun, Jianxin},
title = {PIMT is a novel and potent suppressor of endothelial activation},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.85754}
}
EUVIMED